Exhibit 10.4

CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**],
HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

[**]

Re: Memorandum of Understanding for the Supply of [**] Pens [**]

Dear Ms. [**],

Pursuant to the terms of this letter, US WorldMeds, LLC (“USWM”), Britannia
Pharmaceuticals Ltd. (“BPL”) (collectively the “Purchasers”), and [**], acting
through its [**] business unit (“[**]”) (each, a “Party” and collectively, the
“Parties”) hereby agree and acknowledge the intent by the Parties to move
forward in good faith toward [**] providing the Purchasers certain services (the
“Services”) related to (i) the recommissioning of [**] pen line for the supply
of [**] pens (“[**] Pens”), (ii) the supply of USWM’s requirements of [**] in
the quantities and at the prices set forth herein, and (iii) the [**] and [**]
of [**] for [**] with [**].

In regard to the development and supply of [**], the following terms shall
apply:

•[**]. Within [**] days of the date of last signing below, the Parties shall
resolve a [**] and associated agreement which shall contain the essential
elements of the [**] of the [**], including details concerning the [**], [**],
[**] and [**], [**] and [**] obligations and other requirements (as set forth in
the attached [**] to [**] (the [**])) (the [**]). At the time of signing, it is
believed by [**] that [**] represents an [**] for the [**] with a number of [**]
other [**] and a [**] and [**]. While it is the intention of all the Parties to
proceed to seeking [**] for [**], [**] will additionally have the right, but not
the obligation, to pursue [**] projects with the [**].
•Terms of [**]. The [**] shall include key terms of [**] for the [**].
Furthermore, promptly following the completion of the [**] of the [**], the
Parties shall negotiate and agree in good faith on a [**], which shall include
the key terms of [**] from the [**], amended as necessary to comply with laws
then applicable and any changing conditions and to reflect such other customary
terms and provisions as the parties may agree.
•Payment Terms. [**] will issue periodic invoices to [**] for all amounts due to
[**] hereunder, setting forth in reasonable detail the amounts payable by [**]
under this letter. [**] invoices will be payable within [**] days of [**]
receipt of the respective invoice.
•Deposit. In order to commence work on an expeditious basis and ensure that all
timelines are met, the [**] agree to paying $[**] of the [**] (total $[**]) for
the [**] of [**] within [**] business days of the last signing of this
agreement.
•Non-Assurance. The Parties acknowledge that [**] of the [**] by the [**] is not
assured. As long as a Party uses its commercially reasonable efforts to perform
its obligations under this letter and the [**], that Party shall not be in
default for any failure to achieve any particular result or [**]. For purposes
of clarity, the [**] shall
Page 1 of 3

[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

--------------------------------------------------------------------------------

not be financially accountable for [**] of [**] or additional [**] beyond this
letter and/or the [**] (but shall remain accountable, for the avoidance of
doubt, for payments through [**] totaling $[**] in the [**]), in the event the
[**] are not [**] by the [**].
•Termination. The Parties will use their commercially reasonable best efforts to
seek [**] and [**] of [**] in the [**]. [**] obligation to deliver [**] will
remain in place until [**].

In regard to [**] to be supplied to USWM by [**], the following terms shall
apply:

•RLP Recommissioning. Promptly following the date of last signing below, [**]
will recommission its manufacturing of [**] as set forth in the attached
“Proposal for recommissioning of [**] ([**]) to deliver Apomorphine
hydrochloride” (the “Recommissioning Proposal”).
•Payment Terms. [**] will issue periodic invoices to USWM for all amounts due to
[**] hereunder, setting forth in reasonable detail the amounts payable by USWM
under this letter. [**] invoices will be payable within [**] days of USWM’s
receipt of the respective invoice.
•Deposit. In order to commence work on an expeditious basis and ensure that all
timelines are met, the Purchasers agree to paying [**]% of the cost for the
recommissioning of the [**] line [**] within [**] business days of the last
signing of this agreement.
•The total price for the recommissioning of the [**] line under the
Recommissioning Proposal shall be $[**]; the amount of the deposit is therefore
$[**].
•Price and Quantity. The purchase price of [**] will be $[**] and quantities of
[**] to be produced will be mutually agreed by the Parties based on the outcome
of the [**] and [**] of the [**], with a reasonable amount of [**] produced to
account for the [**] for [**] in [**] of the [**].
•Delivery Date. [**] will target the first delivery of [**] to occur on [**].
[**] agrees that first delivery of [**] shall occur no later than [**]
(“Delivery Date”), though [**] shall endeavor to accelerate such delivery if
reasonably possible. Notwithstanding the foregoing, the Purchasers hereby agree
to pay [**] an additional [**] and [**] ($[**]) as an incentive bonus to [**] if
the [**] are delivered prior to [**] in sufficient quantity to avoid an out of
stock situation.

For further clarity, neither BPL nor USWM assume any liability to [**] in
respect of the obligations of the other Purchaser beyond the [**] this MOU and
any joint liability of the Purchasers hereunder shall be extinguished upon the
[**] of the [**] of the [**] to which such liability relates and the [**] of a
[**] (if applicable) with respect to the events, obligations or milestones to
which such liability relates. Except as expressly set forth in this letter, the
sale and purchase of [**] and [**] shall be governed by [**] Terms and
Conditions of Sale in effect from time to time or such other contractual terms
as the Parties may have agreed or in the future agree in writing.
[Signature Page Follows]

Page 2 of 3
[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

37153181.1 08/14/2020

--------------------------------------------------------------------------------

Acknowledged and agreed upon by:

/s/ [**]________________
[**]
on behalf of
[**]
Date: February 25, 2019

/s/ [**]_________________
[**]
on behalf of
US WorldMeds, LLC
Date: February 22, 2019

/s/ [**]_________________
[**]
on behalf of
Britannia Pharmaceuticals Ltd.
Date: February 20, 2019

Page 3 of 3

[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

37153181.1 08/14/2020

--------------------------------------------------------------------------------

[**] MEDICAL - PHARMACEUTICAL SYSTEMS,
SELF-ADMINISTRATION INJECTION SYSTEMS

Proposal for recommissioning of [**]
to deliver
Apomorphine hydrochloride
Feb 14th 2019

[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

37153181.1 08/14/2020

--------------------------------------------------------------------------------

Proposal for recommissioning of [**] pens

1.Impacted Products:

Catalog No.:Description
Customer

[**][**]
US WorldMeds

2.Project Description

The [**] is designed to provide a convenient means for multiple injections for
the delivery of apomorhine drug. By easy [**] adjustments, the [**] can be [**]
from injection to injection.

The system consists of the following separately supplied components:
•[**]
•Drug Cartridge
•Needle

[**] has been discontinued via project [**], but US WorldMeds has informed [**]
that they would like to restore the [**] to produce additional inventory to
avoid an [**] until the [**] to [**].

Work estimations included in this statement of work:

Development Work:SAP Material UpdatesMaterial Updates:ACR(s)Design Control
Deliverables
•Process Validations
•Risk Management (Design FMEA & Risk Management Report)
•Design & Development Plan
•Design Output Documentation
•Design Verification ([**]), Accelerated Age Testing ([**]), Real-Time Age
Testing & Ship Testing (Vibration, etc.)
•Design Verification Design Review
•Design Transfer Design Review
•ECO release(s)
•ECO104: SAP Data & Document Updates
Customer Deliverables
•Biocompatibility ISO 10993 Compliance Statement
•Material Certifications
Risk Management Summary Report (RMSR)
•Customer External R&D Documents
•Material Statement Quality Statement for Customers

Manufacturing Work:Customer DeliverablesCustomer External Process Validation
Document (VESR)

External Deliverables:
•External R&D Document (ERD) for DV Summary
•Process Validations Molding & Assembly
•External Operations Document (VESR) for Process Validation
•Biocompatibility ISO 10993 Compliance Statement

3.Project costs

The proposal below includes [**] release, and [**] closure for [**]

Project Costs for [**] Production
Total: $[**]
$[**] Plus $[**] incentive bonus for delivering up to [**] pens by [**]. Final
quantity to be determined.
Unit Cost per [**]$[**] (per [**] units)

***Execution of the [**] project is contingent upon [**] commitment

[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

37153181.1 08/14/2020

--------------------------------------------------------------------------------

Exhibit 1: Project Payment Milestones (Draft To be finalized at Kick-off
meeting)

MilestoneTimelines*
Invoice Amount:

#1: MoU execution for Recommission [**] project
•US WorldMeds to issue a PO for $[**]

[**]$[**] ([**]% of [**])
#2: Kick-off Meeting to align on project plan and deliverables for [**]
activities

[**]$[**]
#3: Process Validation – Body, Vial Retainer, Cap

[**]$[**]
#4: Assembly Validation

[**][**]
#5: Design Verification Testing – Accelerated Aging

[**][**]
#6: Design Review, Customer Notification of Change

[**][**]
#7: Completion of project and release of [**] code for sale

[**]$[**]TOTAL FEE$[**] Plus [**] of [**] for [**] + $[**] incentive bonus for
[**] delivery of [**]

[**] = CERTAIN CONFIDENTIAL INFORMATION OMITTED

37153181.1 08/14/2020